The EU Commission sends statements of objections to more than a dozen companies concerning investigations in the pharmaceutical sector (Citalopram / Perindopril)

Accardo, Gabriele

Previous article The US Supreme Court grants certiorari to consider the legality of reverse payment settlements (Actavis) Next article The EU Commission sends a statement of objections to pharmaceutical companies over pay-for-delay agreements (Lundbeck)

30 Jul 2012

The EU Commission sends statements of objections to more than a dozen companies concerning investigations in the pharmaceutical sector (Citalopram / Perindopril)

KEYWORDS

Reference

EU Commission, Citalopram / Perindopril, Press Release, 30 July 2012

European Commission issues Statements of Objections against several pharmaceutical companies* On 25 and 30 July 2012, in relation to the Citalopram case and the Perindopril case respectively, the European Commission sent statements of objections (“SOs”) to more than a dozen companies in connection with these two antitrust investigations in the pharmaceutical sector. The Commission also issued a note highlighting its current enforcement action in pharmaceutical sector

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Gabriele Accardo
Ashurst (Milan)

Italy 102 contributions 28465 visits

Quotation

Gabriele Accardo, The EU Commission sends statements of objections to more than a dozen companies concerning investigations in the pharmaceutical sector (Citalopram / Perindopril), 30 July 2012, e-Competitions Pay-for-delay agreements, Art. N° 58426

Visites 315